Bengaluru: Mylan, a global pharmaceutical company, has announced the commercial launch of its Remdesivir under the brand name DESREM in India to address urgent, unmet needs amid the evolving coronavirus 2019 (COVID-19) pandemic, a company statement said.
The drug is approved for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease.
The company also launched a 24/7 helpline where patients and healthcare practitioners can access information about Mylan’s Remdesivir and its availability.
Mylan released the first batch of its generic Remdesivir (DESREM) and will continue to increase its supply across the country in the wake of the rising demand for the drug. Patients and healthcare practitioners can access information about the availability of DESREM™ in India through Mylan’s 24/7 national helpline number, +91.78299.80066.
Mylan will manufacture DESREM in its state-of-the-art injectable facility in Bangalore, which will work to service the demand in India and other export markets where Mylan has received a license from Gilead for the commercialization of Remdesivir.
The previously announced agreement between Mylan and Gilead is part of a long-standing history between the two organizations to tackle key public health issues in India and around the world, beginning with expanding access to high quality, affordable HIV/AIDS antiretrovirals and now extending its partnership to include COVID-19 treatments.